JPWO2021195067A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021195067A5
JPWO2021195067A5 JP2022558065A JP2022558065A JPWO2021195067A5 JP WO2021195067 A5 JPWO2021195067 A5 JP WO2021195067A5 JP 2022558065 A JP2022558065 A JP 2022558065A JP 2022558065 A JP2022558065 A JP 2022558065A JP WO2021195067 A5 JPWO2021195067 A5 JP WO2021195067A5
Authority
JP
Japan
Prior art keywords
seq
designated
ctat
bispecific antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022558065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519851A5 (https=
JP2023519851A (ja
JP7729833B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023655 external-priority patent/WO2021195067A1/en
Publication of JP2023519851A publication Critical patent/JP2023519851A/ja
Publication of JP2023519851A5 publication Critical patent/JP2023519851A5/ja
Publication of JPWO2021195067A5 publication Critical patent/JPWO2021195067A5/ja
Priority to JP2025135194A priority Critical patent/JP2025161873A/ja
Application granted granted Critical
Publication of JP7729833B2 publication Critical patent/JP7729833B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022558065A 2020-03-23 2021-03-23 武装免疫細胞を産生する際に使用するための二重特異性抗体 Active JP7729833B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025135194A JP2025161873A (ja) 2020-03-23 2025-08-14 武装免疫細胞を産生する際に使用するための二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993080P 2020-03-23 2020-03-23
US62/993,080 2020-03-23
PCT/US2021/023655 WO2021195067A1 (en) 2020-03-23 2021-03-23 Bi-specific antibodies for use in producing armed immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025135194A Division JP2025161873A (ja) 2020-03-23 2025-08-14 武装免疫細胞を産生する際に使用するための二重特異性抗体

Publications (4)

Publication Number Publication Date
JP2023519851A JP2023519851A (ja) 2023-05-15
JP2023519851A5 JP2023519851A5 (https=) 2024-04-02
JPWO2021195067A5 true JPWO2021195067A5 (https=) 2024-04-02
JP7729833B2 JP7729833B2 (ja) 2025-08-26

Family

ID=77892613

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022558065A Active JP7729833B2 (ja) 2020-03-23 2021-03-23 武装免疫細胞を産生する際に使用するための二重特異性抗体
JP2025135194A Pending JP2025161873A (ja) 2020-03-23 2025-08-14 武装免疫細胞を産生する際に使用するための二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025135194A Pending JP2025161873A (ja) 2020-03-23 2025-08-14 武装免疫細胞を産生する際に使用するための二重特異性抗体

Country Status (8)

Country Link
US (1) US20240209084A1 (https=)
EP (1) EP4126954A4 (https=)
JP (2) JP7729833B2 (https=)
CN (1) CN115551890A (https=)
AU (1) AU2021244375A1 (https=)
IL (1) IL296566A (https=)
TW (1) TWI904147B (https=)
WO (1) WO2021195067A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
TW202323295A (zh) * 2021-08-11 2023-06-16 賽昂生醫股份有限公司 用於產生武裝免疫細胞的方法
WO2023143478A1 (en) * 2022-01-27 2023-08-03 Crown Bioscience Inc. Novel anti-cd4 and anti-pd-l1 bispecific antibodies
CN118005806B (zh) * 2024-02-08 2026-01-30 北京市眼科研究所 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用
CN121248779A (zh) * 2024-06-25 2026-01-02 冕屹立生物技术(上海)有限公司 靶向人cd3分子的抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US9611325B2 (en) * 2014-07-21 2017-04-04 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody HER2xCD3
US10519248B2 (en) * 2014-07-25 2019-12-31 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
RS60739B1 (sr) * 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
CN104829725A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd133×cd3的构建及应用
US11649435B2 (en) * 2015-08-28 2023-05-16 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US11702477B2 (en) * 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
WO2018049261A1 (en) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
WO2018177371A1 (en) * 2017-03-29 2018-10-04 Taipei Medical University Antigen-specific t cells and uses thereof
EP3802595A1 (en) * 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment

Similar Documents

Publication Publication Date Title
Felices et al. Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells
Qi et al. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1
Zhang et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
Chen et al. Bispecific antibodies in cancer immunotherapy
JP2022116230A5 (https=)
CN108124445B (zh) Ctla4抗体、其药物组合物及其用途
CN107880128B (zh) 一种抗cd19的全人源抗体或抗体片段及其方法和应用
CN109055380B (zh) 一种通用型car-t细胞的制备方法
RU2018128462A (ru) Модифицированные клетки для иммунотерапии
JP2015527070A5 (https=)
CN103833852A (zh) 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
Bogen et al. Design of a trispecific checkpoint inhibitor and natural killer cell engager based on a 2+ 1 common light chain antibody architecture
WO2022135536A1 (zh) Cd3人源化抗体及其应用
CN104592391B (zh) 一种双特异性抗体EpCAM×CD3的构建及应用
CN105194661A (zh) 时空可调性抑制病理性靶细胞的系统
EP3402818A1 (en) Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
CN104829725A (zh) 一种双特异性抗体cd133×cd3的构建及应用
WO2023071676A1 (zh) 一种抗her2/抗pd-l1双功能抗体及其应用
Liang et al. A CLDN18. 2-targeting bispecific T cell co-stimulatory activator for cancer immunotherapy
Vyas et al. Mono-and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia
JPWO2021195067A5 (https=)
CN120035658A (zh) Nkg2d工程化细胞及其组合物
TW201920272A (zh) 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用
Harwardt et al. Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
WO2015172341A1 (zh) 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体